FAQ/Help |
Calendar |
Search |
Today's Posts |
08-29-2012, 05:31 PM | #1 | |||
|
||||
Member
|
|
|||
Reply With Quote |
"Thanks for this!" says: | soccertese (08-29-2012) |
08-29-2012, 09:43 PM | #2 | ||
|
|||
Senior Member
|
Thanks for bringing this paper to our attention.
First, let me apologize: I'm unable to access the whole paper; my comments are based on the abstract alone. My take on it is that the effect is small: the reduction in the UPDRS score was 4.69 points. That's out of 176 [1]. So, we have less than a 3% improvement. Reference [1] http://img.medscape.com/fullsize/701...8977_UPDRS.pdf John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
"Thanks for this!" says: | Conductor71 (08-29-2012) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
inhaled l-dopa - Civitas starts Phase 2a trial of Parkinson’s treatment | Parkinson's Disease | |||
Parkinson’s Disease: Treatment Guideline Update, 2010-2011Parkinson’s Disease: Treatm | Parkinson's Disease | |||
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Diseas | Parkinson's Disease |